0000950170-23-033475.txt : 20230719 0000950170-23-033475.hdr.sgml : 20230719 20230719122139 ACCESSION NUMBER: 0000950170-23-033475 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230714 FILED AS OF DATE: 20230719 DATE AS OF CHANGE: 20230719 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kilcoyne Adrian CENTRAL INDEX KEY: 0001857963 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38914 FILM NUMBER: 231096112 MAIL ADDRESS: STREET 1: 533 AIRPORT BLVD. STREET 2: SUITE 400 CITY: BURLINGAME STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celularity Inc CENTRAL INDEX KEY: 0001752828 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831702591 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (908) 768-2170 MAIL ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: GX Acquisition Corp. DATE OF NAME CHANGE: 20180912 4 1 ownership.xml 4 X0508 4 2023-07-14 0001752828 Celularity Inc CELU 0001857963 Kilcoyne Adrian C/O CELULARITY INC. 170 PARK AVENUE FLORHAM PARK NJ 07932 false true false false Chief Medical Officer false Class A Common Stock 2023-07-14 4 A false 875000 0.00 A 1175000 D These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs are subject to (i) time-based vesting over a three-year period, with 25% vesting on the one-year anniversary of the grant date, 25% vesting on the two-year anniversary of the grant date, and the remainder vesting on the three-year anniversary of the grant date, and (ii) performance-based vesting based on the Issuer's stock price, and in each case subject to the Reporting Person's continuous service on each vesting date. Reflects shares underlying RSUs subject to vesting. /s/ Kyle Fletcher, Attorney-in-Fact 2023-07-19